Quantitative Investment Management LLC Invests $11.03 Million in Novo Nordisk A/S $NVO

Quantitative Investment Management LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 198,699 shares of the company’s stock, valued at approximately $11,025,000. Novo Nordisk A/S accounts for about 1.5% of Quantitative Investment Management LLC’s holdings, making the stock its 15th largest holding.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Beacon Financial Group lifted its position in Novo Nordisk A/S by 4.3% during the third quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock worth $239,000 after acquiring an additional 178 shares during the last quarter. Kavar Capital Partners Group LLC boosted its holdings in shares of Novo Nordisk A/S by 0.6% during the third quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock worth $1,811,000 after acquiring an additional 200 shares during the period. SeaBridge Investment Advisors LLC grew its position in shares of Novo Nordisk A/S by 5.7% in the third quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company’s stock valued at $207,000 after purchasing an additional 200 shares during the last quarter. Joel Isaacson & Co. LLC grew its position in shares of Novo Nordisk A/S by 1.0% in the third quarter. Joel Isaacson & Co. LLC now owns 21,084 shares of the company’s stock valued at $1,170,000 after purchasing an additional 200 shares during the last quarter. Finally, Revolve Wealth Partners LLC increased its stake in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Zacks upgraded Novo Nordisk from “strong sell” to “hold,” a modest vote that may limit further downside from some retail/quant sellers. Read More.
• Positive Sentiment: Novo entered a WHO Foundation partnership focused on cardio‑renal‑metabolic diseases and committed funding for obesity/diabetes efforts in low‑ and middle‑income countries — a reputational and long‑term access play that supports the company’s global public‑health positioning. Read More.
• Neutral Sentiment: Novo Holdings published 2025 annual results showing income and investment returns; while the report is routine, its figures are being viewed through the lens of Novo Nordisk’s share‑price swing. Read More.
• Neutral Sentiment: India’s regulator warned drugmakers about direct or surrogate advertising for weight‑loss drugs, a policy development that adds regulatory complexity across a large and fast‑growing market but is industry‑wide rather than Novo‑specific. Read More.
• Negative Sentiment: FDA issued a warning letter over failures in post‑marketing adverse event reporting tied to semaglutide, triggering immediate regulatory risk and heightened compliance scrutiny that can hurt investor confidence and valuation. Read More.
• Negative Sentiment: Regulatory news sparked sharp market reaction and legal attention: a class‑action/investor probe (Pomerantz) was announced and some articles report a very steep intraday drop tied to the FDA news, increasing the chance of litigation and reputational/financial fallout. Read More.
• Negative Sentiment: Analysts have reacted: TD Cowen and others trimmed ratings/targets, and coverage notes the hit to Novo Holdings’ controlling‑shareholder asset value — both amplify selling pressure. Read More.
• Negative Sentiment: Competitive pressure from Eli Lilly (big investments and programs to expand GLP‑1 access) is a strategic negative for Novo’s long‑term market share and pricing power in GLP‑1s. Investors should factor stronger Lilly initiatives into longer‑term growth forecasts. Read More.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price objective on the stock in a research report on Tuesday, March 3rd. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. CICC Research began coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They issued an “outperform” rating and a $73.50 target price for the company. Finally, HSBC restated a “hold” rating and issued a $54.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Four investment analysts have rated the stock with a Buy rating and nineteen have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $49.93.

Novo Nordisk A/S Trading Down 2.0%

Shares of Novo Nordisk A/S stock opened at $38.04 on Friday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 12-month low of $35.85 and a 12-month high of $82.57. The company has a market capitalization of $169.83 billion, a price-to-earnings ratio of 10.96 and a beta of 0.73. The firm’s 50-day moving average price is $50.43 and its two-hundred day moving average price is $51.92.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The company had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. On average, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. This represents a yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s payout ratio is currently 23.63%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.